Bausch + Lomb can trace its roots back to 1853 when two German immigrants to the US, John Bausch, and Henry Lomb made a small workshop which manufactured monocles. The business was so successful that by 1861, they were also manufacturing rubber eyeglass frames, as well as other eyewear products.
The company continued to grow substantially over the decades that followed. In 1945, Bausch + Lomb even refined the optics for the CinemaScope, which made movies more popular and caused theaters to double the width of their screens in movie houses.
Today, the company is best known for contact lenses, contact lens solutions, eye drops, and vitamins for the eyes. Bausch + Lomb operate as a subsidiary of Valeant Pharmaceuticals International. This global company operates in 36 countries and has more than 13,000 employees.
In July 2018, the company was waiting for approval from the FDA to produce a low-concentrated formula of loteprednol ophthalmic corticosteroid which can be used for the treatment of post-operative inflammation and pain following ocular surgery. The product is expected to be approved sometime in 2019.
Company headquarters are located in Bridgewater, New Jersey.
Bausch + Lomb can trace its roots back to 1853 when two German immigrants to the US, John Bausch, and Henry Lomb made a small workshop which manufactured monocles. The business was so successful that by 1861, they were also manufacturing rubber eyeglass frames, as well as other eyewear products.
The company continued to grow substantially over the decades that followed. In 1945, Bausch + Lomb even refined the optics for the CinemaScope, which made movies more popular and caused theaters to double the width of their screens in movie houses.
History
Today, the company is best known for contact lenses, contact lens solutions, eye drops, and vitamins for the eyes. Bausch + Lomb operate as a subsidiary of Valeant Pharmaceuticals International. This global company operates in 36 countries and has more than 13,000 employees.
In July 2018, the company was waiting for approval from the FDA to produce a low-concentrated formula of loteprednol ophthalmic corticosteroid which can be used for the treatment of post-operative inflammation and pain following ocular surgery. The product is expected to be approved sometime in 2019.
Company headquarters are located in Bridgewater, New Jersey.